Physicians' Academy for Cardiovascular Education

SGLT2 inhibition in CKD: Discussing the key questions & evidence

Meeting report with presentation slides and video of a PACE-CME symposium held during ISN-WCN 2019 in Melbourne on novel therapeutic approaches with SGLT2i & CKD (video will be posted soon)

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD
Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.

ISN-WCN 2019 Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - May 22, 2019 - ISN-WCN 2019 - Mark Cooper, MD
Mark Cooper addresses the role of SGLT2 inhibitors in patients with diabetic kidney disease with regard to effects on renal function.

ISN-WCN 2019 Mark Cooper addresses the role of SGLT2 inhibitors in patients with diabetic kidney disease with regard to effects on renal function.

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada
Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.

ISN-WCN 2019 Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.

Slides: The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

Slides (presentation) - Apr. 15, 2019 - Melbourne, Australia - Prof. David Cherney, MD University of Toronto Toronto, Canada - PACE-CME symposium held during ISN-WCN 2019
This lecture by prof. David Cherney was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

Slides (presentation) - Apr. 15, 2019 - Melbourne, Australia - Mark Cooper, MD Monash University Melbourne, Australia - PACE-CME symposium held during ISN-WCN 2019
This lecture by prof. Mark Cooper was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: The known and unknown of SGLT2 inhibition in CKD

Slides (presentation) - Apr. 15, 2019 - Melbourne, Australia - Prof. Carol Pollock, MD University of Sydney Sydney, Australia - PACE-CME symposium held during ISN-WCN 2019
This lecture by prof. Carol Pollock was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

SGLT2 inhibition in CKD: Discussing the key questions & evidence
SGLT2 inhibition in CKD: Discussing the key questions & evidence